tbuckley/cabot-search huggingface dataset:
Tc-99m Sestamibi Uptake in Tuberculosis of the Breast
Authors: HITOYA OHTA, HIROHITO ICHII, AKIRA ARIMOTO, MINORU UKIKUSA, HIROJI AWANE
Journal: Clinical Nuclear Medicine (1998)

A 75-year-old woman was seen because of a painful breast mass. Tc-99m sestamibi scintimammography showed uptake in the mass, suggesting malignancy. The mass ulcerated spontaneously and discharged. Mycobacterium tuberculosis was positive on examination of the discharge.
The Next Frontier for Stem Cell Transplantation
Authors: Lucy A. Godley, Koen van Besien
Journal: JAMA (2010)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
728. Safety and Bioactivity of rAAV2-hAAT in alpha-1 Antitrypsin-Deficient Patients in a Phase I Clinical Trial
Authors: Mark L. Brantly, Terry Spencer, Carolyn T. Spencer, Thomas J. Conlon, Sihong Song, Margaret Humphries, Barry J. Byrne, Richard O. Snyder, Terence R. Flotte
Journal: Molecular Therapy (2006)

INTRODUCTION: Recombinant adeno-associated virus (rAAV) vectors are capable of sustained expression of therapeutic proteins when administered to skeletal muscle. A single injection of a rAAV2 vector in mice resulted in sustained secretion of human alpha-1 antitrypsin (hAAT) at levels that would be therapeutic for prevention of lung disease in humans (11,000 nM). There is currently no definitive therapy for these patients, since protein replacement products are in short supply and require weekly intravenous infusions. Recently, we completed the ongoing preclinical testing (mouse, rabbit, and primate) of the rAAV2-hAAT vector in muscle, completed clinical grade production of rAAV2-hAAT, and initiated a phase I trial of rAAV-hAAT gene therapy in patients with AAT deficiency. MEHODS: The trial is an open-labeled, single administration study being performed in a total of 15 adult AAT- deficient patients. Five cohorts of three subjects each are being used with a dose escalation between cohorts. The dosages for the four cohorts range from 2 × 1012 vector genomes (vg) per patient to 2 × 1014 vg/patient. Subjects are screened and allowed a 28-day period for washout of protein replacement. An ultrasound-guided injection technique is used to avoid intravascular injection. The study endpoints address safety with examinations of the injection site, hematology, chemistry, coagulation studies, and pulmonary function tests. Biological activity of the vector is assessed by detection of normal M-variant hAAT protein by ELISA. Serum is also assayed for antibodies and lymphocyte proliferation responses to rAAV2 capsid and to AAT. Blood and semen DNA are also being assayed for vector DNA sequences. RESULTS: At the time of submission of this abstract, twelve subjects have been treated, and there have been no vector-related adverse events to date. All patients have demonstrated increases in anti-AAV2 capsid protein titers by ELISA, but none have shown increases in anti-hAAT antibody titers or in lymphocyte proliferation responses. Patients in the cohorts 2–4 show PCR evidence of vector DNA in the blood within the first 14 days, but without obvious ill effects. At least one subject in cohorts 3 shows evidence of M-AAT expression in the range of 50–100 nm. CONCLUSIONS: Preliminary evidence of the safety and bioactivity of rAAV2-hAAT are being generated. These support the feasibility of future clinical studies, including one recently begun with rAAV1, a serotype that shows a 500–1000-fold greater bioactivity than the current rAAV2 vector in mice.
Antihypertensive Properties of Furosemide
Authors: MICHAEL DAVIDOV, NIKOS KAKAVIATOS, FRANK A. FINNERTY
Journal: Circulation (1967)

The antihypertensive properties of single doses of furosemide were evaluated in 113 patients. Doses over 120 mg consistently produced a fall in arterial pressure whereas smaller doses did not. Thus 20 of 22 patients (90%) who received more than 120 mg had a 26 ± 6% average reduction in mean arterial pressure. The hypotensive action began in 30 to 45 minutes, the nadir of the decrease occurred between 2 and 2½ hours, and the hypotension usually lasted 10 to 12 hours. Repeated weekly doses of furosemide over a 2-month period in six patients were not associated with development of drug resistance. The antihypertensive properties of doses of furosemide of more than 120 mg seemed to be of about the same potency as ethacrynic acid. The antihypertensive effect of high doses of furosemide did not seem to be related to the diuretic effect or to the decrease in plasma volume. These studies have demonstrated that doses of furosemide of more than 120 mg consistently decreased arterial pressure. The usefulness of this agent in the long-term management of hypertension remains to be determined.
Oral steroid improves bullous pemphigoid-like clinical manifestations in non-Herlitz junctional epidermolysis bullosa with COL17A1 mutation
Authors: E. Mabuchi, N. Umegaki, H. Murota, T. Nakamura, K. Tamai, I. Katayama
Journal: British Journal of Dermatology (2007)

Non-Herlitz junctional epidermolysis bullosa (JEB-nH), a nonlethal variant of junctional epidermolysis bullosa (JEB), is an autosomal recessive disorder characterized by separation of the dermal-epidermal junction. JEB-nH is caused by mutations in several genes and lack of the COL17A1 gene product may lead to skin fragility. A 41-year-old Japanese man with JEB-nH, featuring mutations in the gene encoding type XVII collagen, presented with great blisters over his entire body accompanied by severe itching and eosinophilia usually observed in bullous pemphigoid (BP). To our knowledge, our patient is the first with JEB-nH to be treated successfully with an oral steroid to control his skin affliction, symptoms and eosinophilia. This suggests that in the case of JEB-nH with eosinophilia caused by some secondary immune activation, oral steroids may constitute an alternate therapy to improve aggravated skin conditions and severe itching, both of which tend to show resistance to usual dermatological treatments.
ON THE TREATMENT OF FIBROID TUMORS IN THE WOMB BY THE INJECTION OF ERGOT INTO THEIR SUBSTANCE.Read before the Illinois State Medical Society, May 21, 1891.
Authors: J. SCHENCK
Journal: JAMA (1891)

Fibroid growths in the walls of the womb produce such serious symptoms and cause so great an amount of suffering that I believe that any method of treatment which has afforded relief or produced a cure should be placed before the profession. It has been repeatedly demonstrated that fibroid tumors in the walls of the womb may be either checked in their growth, strangulated until local necrosis is produced, or forced out of the uterine walls by contractions produced by the free and long continued use of ergot. The methods by which the remedies have been administered are, by hypodermatic injections; by the mouth; or by suppositories per rectum or vaginum. The inoculation of a virus to prevent or modify threatened diseases, has been practiced for about two hundred years. The most familiar examples are those against small-pox, anthrax, hydrophobia, cholera, scarlet fever, and finally, tuberculosis. Hypodermatic medication has been
Hemodynamic, Autonomic, and Vascular Effects of Exposure to Coarse Particulate Matter Air Pollution from a Rural Location
Authors: Robert D. Brook, Robert L. Bard, Masako Morishita, J. Timothy Dvonch, Lu Wang, Hui-yu Yang, Catherine Spino, Bhramar Mukherjee, Mariana J. Kaplan, Srilakshmi Yalavarthi, Elif A. Oral, Nevin Ajluni, Qinghua Sun, Jeffrey R. Brook, Jack Harkema, Sanjay Rajagopalan
Journal: Environmental Health Perspectives (2014)

Fine particulate matter (PM) air pollution is associated with numerous adverse health effects, including increased blood pressure (BP) and vascular dysfunction. Coarse PM substantially contributes to global air pollution, yet differs in characteristics from fine particles and is currently not regulated. However, the cardiovascular (CV) impacts of coarse PM exposure remain largely unknown.Our goal was to elucidate whether coarse PM, like fine PM, is itself capable of eliciting adverse CV responses.We performed a randomized double-blind crossover study in which 32 healthy adults (25.9 ± 6.6 years of age) were exposed to concentrated ambient coarse particles (CAP; 76.2 ± 51.5 μg/m(3)) in a rural location and filtered air (FA) for 2 hr. We measured CV outcomes during, immediately after, and 2 hr postexposures.Both systolic (mean difference = 0.32 mmHg; 95% CI: 0.05, 0.58; p = 0.021) and diastolic BP (0.27 mmHg; 95% CI: 0.003, 0.53; p = 0.05) linearly increased per 10 min of exposure during the inhalation of coarse CAP when compared with changes during FA exposure. Heart rate was on average higher (4.1 bpm; 95% CI: 3.06, 5.12; p < 0.0001) and the ratio of low-to-high frequency heart rate variability increased (0.24; 95% CI: 0.07, 0.41; p = 0.007) during coarse particle versus FA exposure. Other outcomes (brachial flow-mediated dilatation, microvascular reactive hyperemia index, aortic hemodynamics, pulse wave velocity) were not differentially altered by the exposures.Inhalation of coarse PM from a rural location is associated with a rapid elevation in BP and heart rate during exposure, likely due to the triggering of autonomic imbalance. These findings add mechanistic evidence supporting the biological plausibility that coarse particles could contribute to the triggering of acute CV events.
Multiple keratoacanthomas: a case report with evidence of regression with thymic hormone
Authors: M.P. FOSCHINI, P. MAGNANI, F. MARCONI, M.G. COOK, V. EUSEBI
Journal: British Journal of Dermatology (1991)

A case of multiple keratoacanthomas (KAs) arising on sun‐damaged skin in a 63‐year‐old male is reported. The patient showed a moderate elevation of the T‐helper/T‐suppressor ratio. Therapy with thymic hormone appeared to improve the condition.
The role of proliferator-activated receptor γ coactivator–1α in the fatty-acid–dependent transcriptional control of interleukin-10 in hepatic cells of rodents
Authors: Joseane Morari, Adriana S. Torsoni, Gabriel F. Anhê, Erika A. Roman, Dennys E. Cintra, Laura S. Ward, Silvana Bordin, Lício A. Velloso
Journal: Metabolism (2009)
Slater revisited: 6 year follow up study of patients with medically unexplained motor symptoms
Authors: H. L Crimlisk, K. Bhatia, H. Cope, A. David, C D. Marsden, M. A Ron
Journal: BMJ (1998)

To investigate psychiatric and neurological morbidity, diagnostic stability, and indicators of prognosis in patients previously identified as having medically unexplained motor symptoms.Follow up study.National Hospital for Neurology and Neurosurgery, London--a secondary and tertiary referral hospital for neurological disorders.73 patients with medically unexplained motor symptoms admitted consecutively in 1989-91. 35 (48%) patients had absence of motor function (for example, hemiplegia) and 38 (52%) had abnormal motor activity (for example, tremor, dystonia, or ataxia).Neurological clinical diagnosis at face to face reassessment by a neurologist and a psychiatric diagnosis after a standardised assessment interview--the schedule for affective disorders and schizophrenia--conducted by a psychiatrist.Good follow up data were available for 64 subjects (88%). Only three subjects had new organic neurological disorders at follow up that fully or partly explained their previous symptoms. 44/59 (75%) subjects had had psychiatric disorders; in 33 (75%) patients, the psychiatric diagnosis coincided with their unexplained motor symptoms. 31/59 (45%) patients had a personality disorder. Three subjects had developed new psychiatric illnesses at follow up, but in only one did the diagnosis account for the previous motor symptoms. Resolution of physical symptoms was associated with short length of symptoms, comorbid psychiatric disorder, and a change in marital status during follow up.Unlike Slater's study of 1965, a low incidence of physical or psychiatric diagnoses which explained these patients' symptoms or disability was found. However, a high level of psychiatric comorbidity existed.
A User's Guide to the NINDS rt-PA Stroke Trial Database
Authors: Robert J Dachs, John H Burton, Jeremy Joslin
Journal: PLoS Medicine (2008)

In 1995, the NINDS rt-PA study documented an improvement in neurologic outcomes at three months for those patients given rt-PA within 3 hours of onset of an acute ischemic stroke.• This trial has become the sentinel study supporting the use of rt-PA in acute ischemic stroke.
Perspectives on Mitral-Valve Prolapse
Authors: Rick A. Nishimura, Michael D. McGoon
Journal: New England Journal of Medicine (1999)

More than three decades ago, Barlow and Bosman described a constellation of clinical findings consisting of non-ejection systolic clicks and a late systolic murmur, T-wave abnormalities, and systolic aneurysmal billowing of the posterior mitral leaflet into the left atrium on left ventriculography.1 Since then, the syndrome of mitral-valve prolapse has been portrayed as the most common form of valvular heart disease, with a reported prevalence of 5 to 10 percent in the general population and an even higher prevalence among young women.2,3 Though it is a predominantly benign condition, devastating complications have been ascribed to mitral-valve prolapse, including cerebral . . .
FRIENDLY SOCIETIES AND THE AUSTRALIAN PROFESSION
Authors: C. Stanton Crouch
Journal: JAMA (1918)

<h3>To the Editor:</h3> —I have been directed to inform you of the dispute that has been in existence for some months between the Friendly Societies of Victoria and the British Medical Association. The lodge doctors have been paid for the past forty years on an average as little as 14s. per annum for the town; this includes attendance on the member and his family and works out at four persons for each member; for the country the average is 16s. per annum per member for the lodge doctor. For a considerable period of time we held negotiations with the associated lodges called the "Friendly Societies Association" with a view to having the rate of remuneration increased. As the Friendly Societies refused our demands, 100 per cent. of the town members and 96 per cent. of the country members of the British Medical Association on the 31st of last October gave
Neurologic Disorders Following Live Measles-Virus Vaccination
Authors: Philip J. Landrigan
Journal: JAMA (1973)

From 1963 through 1971, eighty-four cases of neurologic disorders with onset less than 30 days after live measles-virus vaccination were reported in the United States. Thirteen could be adequately accounted for by causes other than vaccine, and another 11 were uncomplicated febrile convulsions probably related to vaccination. One case met diagnostic criteria for subacute sclerosing panencephalitis. The remaining 59 showed clinical features of encephalitis or encephalopathy. Causes of these cases could not be established, but 45 (76%) had onset between 6 and 15 days after vaccination; this clustering suggests that some may have been caused by vaccine. From 1963 through 1971, 50.9 million doses of measles vaccine were distributed, and, therefore, incidence of the reported neurologic disorders was 1.16 per million doses. Risk of encephalitis following measles infection is one per thousand cases.
Persistent bite reactions responsive to photochemotheraphy
Authors: B.E. Beacham, D. Kurgansky
Journal: British Journal of Dermatology (1990)

Journal Article Persistent bite reactions responsive to photochemotheraphy Get access B.E. Beacham, B.E. Beacham Department of Dermatology, University of Maryland School of Medicine, Baltimore, MD 21201, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar D. Kurgansky D. Kurgansky Department of Dermatology, University of Maryland School of Medicine, Baltimore, MD 21201, U.S.A. Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 123, Issue 5, 1 November 1990, Pages 693–694, https://doi.org/10.1111/j.1365-2133.1990.tb01491.x Published: 01 November 1990
Measurement and Precision in Surgery
Authors: John H. Wulsin
Journal: JAMA (1969)

Whether they like it or not, surgeons today must taste and digest a smorgasbord of scientific data about their patients, data derived from an ever-widening variety of instruments designed to supplement the information already available to us through the five senses. While most surgeons, with understandable frustration, react to this mass of facts as often irrelevant and unnecessary to proper patient care, still our scientific curiosity is titillated by the promise of new machinery and of new avenues to reach old goals. This volume represents a symposium sponsored by the Royal College of Surgeons (England) and designed to make surgeons more comfortable with the measurements and procedures infiltrating into the wards and operating suites. The papers, largely the work of non-surgeons, present various topics in abbreviated technical language which will provoke the interested reader to further study but will leave the casual browser annoyed with his own ignorance. We can
Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity—Letter
Authors: Ting-Chao Chou
Journal: Cancer Research (2011)

I read with interest the recent article by Jia and colleagues (1), which presents in Figure 5B a plot for drug combination synergy determination by using the x-axis with “Proportion Surviving (E)” and the y-axis with “Interaction Index.” This plot is very similar in form to the Fa–CI plot introduced by Chou and Talalay (2), which has been cited in more than 2,000 articles where the x-axis is noted as “Fraction Affected (Fa)” (e.g., fraction inhibited or fraction killed) and the y-axis as “Combination Index (CI).” One cannot be convinced that fractional survival equals fraction kill by simple logic. I believe it is important to straighten out this contradiction, because drug combination or synergy determination (2–6) is widely used for cancer, AIDS, and other diseases. In the Jia article (1), the E–Interaction Index plot is based on a theoretical article by Lee and colleagues (7), using the probabilistic statistical approach rather than the deterministic mass-action law approach. I have serious reservations for its feasibility and question the reason why the new method (7) contradicts the widely used, preexisting CI method (2–3). On examining the Lee article (7), I have noticed that its Eqs. 3 to 8 and 12 to 14 were directly taken from Chou's and Chou–Talalay's major equations since 1973 (2–6) by substituting existing symbols with different symbols. The substitution of symbols by itself does not constitute a “derivation.” In addition, by comparing Eqs. 3 and 4, then “E ≠ E” and it is unclear where Eq. 2 “Emax” came from. Arbitrarily, alternating Chou–Talalay's equation with “E” in Eq. 4 is not what the original had intended.My concerns focus on the following issues. First, is drug combination synergy quantification a mass-action law issue or a statistical issue? If the latter is the case, then how can the probabilistic/statistical approach be used to derive the deterministic/pharmacodynamic equations or algorithms for a quantitative diagnostic plot? Also, why is the statistical approach allowed to contradict the equations/algorithms derived from the mass-action law? Second, the quantification of synergism (CI < 1), additive effect (CI = 1), and antagonism (CI > 1) were mathematically defined by Chou and Talalay in 1984 (2) following the systematic derivation of more than 300 mechanism specific equations (2–4), yet Lee and colleagues (7) attributed these definitions to Loewe without reference.See the Response, p. 2794T-C. Chou holds the copyright to the software package CompuSyn (6), which is used to simulate dose–effect analysis and synergy quantification in drug combinations.
Familial Aggregation of Lipids and Lipoproteins and Early Identification of Dyslipoproteinemia
Authors: John A. Morrison
Journal: JAMA (1983)

We examined the hypothesis that familial aggregation of lipids and lipoproteins facilitates within-family identification and hyperlipoproteinemia. We studied 841 offspring and 1,236 siblings of normocholesterolemic probands, 833 offspring and 1,194 siblings of hypercholesterolemic probands, 806 offspring and 1,099 siblings of normotriglyceridemic probands, and 877 offspring and 1,108 siblings of hypertriglyceridemic probands in the Lipid Research Clinics Collaborative Family Study Program. As the categorization of probands' hypercholesterolemia or hypertriglyceridemia increased from sporadic, to persistent, to severe, the percentage of hypercholesterolemic or hypertriglyceridemic offspring and siblings increased. Close sibling and parent-offspring lipid and lipoprotein risk factor associations in hypercholesterolemic and hypertriglyceridemic family units during and after the period of shared common-household environment facilitate within-family identification of dyslipoproteinemia and suggest potential sharing of coronary heart disease risk. (<i>JAMA</i>1983;250:1860-1868)
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy
Authors: Lenore J Launer, Michael E Miller, Jeff D Williamson, Ron M Lazar, Hertzel C Gerstein, Anne M Murray, Mark Sullivan, Karen R Horowitz, Jingzhong Ding, Santica Marcovina, Laura C Lovato, James Lovato, Karen L Margolis, Patrick O'Connor, Edward W Lipkin, Joy Hirsch, Laura Coker, Joseph Maldjian, Jeffrey L Sunshine, Charles Truwit, Christos Davatzikos, R Nick Bryan
Journal: The Lancet Neurology (2011)